Suzhou-based RNA interference (RNAi) therapeutics developer SanegeneBio has entered into a partnership with compatriot firm Huadong Medicine Co., Ltd (SHE: 000963). The collaboration will utilize SanegeneBio’s Ligand and Enhancer Assisted Delivery (LEAD) technology platform to develop small interfering RNA (siRNA) drugs targeting chronic metabolic diseases, with the potential to expand into other therapeutic areas. Financial details of the agreement have not been disclosed.
SanegeneBio’s Proprietary Technology and Its Applications
Founded in 2021 and with operations in both China and the US, SanegeneBio possesses a proprietary chemical modification platform and hepatic and extrahepatic delivery platforms. These enable tissue-specific delivery of a broad spectrum of RNA therapeutics, efficiently silencing disease-causing genes.- Flcube.com
